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Metabolic disorders deriving from the non-responsiveness of target organs to hormones, which
manifest clinically similar to the deficiency of a given hormone itself, derive from molecular
alterations affecting specific hormone receptors.
Pseudohypoparathyroidism (PHP) and related disorders exemplify an unusual form of hor-
mone resistance as the underlying molecular defect is a partial deficiency of the α subunit of
the stimulatory G protein (Gsα), a key regulator of cAMP signaling pathway, or, as more re-
cently described, of downstream effector proteins of the same pathway, such as PKA regula-
tory subunit 1A (R1A) and phosphodyestarase type 4D (PDE4D). In this group of diseases,
resistance to hormones such as PTH, TSH, gonadotropins and GHRH may be variably present,
so that the clinical and molecular overlap among these different but related disorders represents
a challenge for endocrinologists as to differential diagnosis and genetic counseling.
This review will describe the presenting features of multiple resistance in PHP and related
disorders, focusing on both our current understanding and future challenges.
© 2017.
Introduction
Metabolic disorders deriving from the non-responsiveness of target organs to hormones, which manifest clinically similar to
the deficiency of a given hormone itself, usually derive from molecular alterations affecting specific hormone receptors. The
pleiotropic effect of multiple hormone resistance is a consequence of its different pathophysiology compared to single hormone
resistances, as pathologic features arise from the lack of activation of downstream signaling pathways rather than of the receptor
itself.
The interaction between agonists (polypeptide hormones monoamines, neurotransmitters, PGs and extracellular Ca ⁠+) and their
specific GPCRs activates G proteins, a superfamily of heterotrimeric guanine nucleotide binding proteins composed of three func-
tionally distinct subunits (alpha, beta and gamma), which specificity depend on the alpha subunit. Sixteen mammalian α subunits
have been described, which vary in range of expression and specificity of receptor-effector coupling, that trigger the activation
of effectors, enzymes and ion channels, inducing both short-term effects on hormone secretion, neurotransmission and muscle
contraction and long term effects on gene transcription [1–5].
The alpha subunit of the stimulatory G protein (Gsα) is responsible for the cAMP-mediated signaling by activating the enzyme
adenylyl cyclase, which stimulates the cAMP formation and the subsequent protein kinase A (PKA) activation. Molecular alter-
ations that deregulate the Gsα/cAMP/PKA pathway mostly affect the signaling of PTH/PTHrp, activated by the PTHR1 receptor,
and, with different severity, the signaling of additional hormones, including TSH, epinephrin and calcitonin (Fig. 1).
In the past years, the GPCRs abnormal signal transduction causing resistance to multiple hormones was demonstrated to
be secondary to molecular defects affecting the Gsα, a clinical condition named as Pseudohypoparathyroidism (PHP), or other
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Fig. 1. Schematic representation of the cAMP signalling pathway. After hormone stimulation of the G-protein-coupled receptor (GPCR), the activated α subunit
of the stimulatory G protein (Gsα; encoded by GNAS) interacts with the adenylate cyclase (AC) promoting cAMP production, that, interacting with the cAMP-de-
pendent protein kinase type 1α regulatory subunits (R; encoded by PRKAR1A), determines the activation of the protein kinase A (PKA) catalytic subunit (C). The
cAMP-specific 3′,5′-cyclic phosphodiesterase 4D (PDE4D; encoded by PDE4D) convert cAMP to AMP to switch off the signal.
downstream molecular effectors, including the Protein Kinase cAMP-Dependent Type 1 Regulatory Subunit Alpha (Prkar1a) and
the Phosphodiesterase 4D (Pde4d), that were associated with Acrodysostosis (ACRDYS) [6–11] (Fig. 2).
PHP is the first hormone resistance syndrome ever described, and the term now encompasses a heterogeneous group of rare
and impairing metabolic diseases, all characterized by end-organ resistance to the action of different hormones, primarily PTH.
Main clinical characteristics are hypocalcemia and hyperphosphoremia associated with elevated PTH levels, frequently encom-
passing additional heterogeneous features, referred to as Albright's hereditary osteodystrophy (AHO), such as brachydactyly, ec-
topic ossifications, short stature and mental retardation [8,12,13].
ACRDYS describes a group of rare skeletal disorders characterized by severe brachydactyly, nasal and/or midfacial hypopla-
sia and variable intellectual/developmental/behavioural disabilities. Frequently observed features are the resistance to multiple
hormones that bind to GPCRs (including PTH and TSH), progressive growth failure with short stature, advanced bone age and
obesity [14].
The overlap between different but related disorders affecting the cAMP pathway represents a challenge to perform differential
diagnosis and genetic counseling, and highlights the need for novel and updated classification models [12,15,16].
Pathophysiology
The first description of patients affected with PHP dates back to 1942, when patients with normal renal function, hypocal-
cemia, hyperphosphatemia and raised serum PTH levels were reported [17,18]. In contrast with patients affected by primary hy-
poparathyroidism, PHP patients presented immunologically and biologically active PTH in the parathyroid glands and an unre-
sponsiveness to the calcium-mobilizing or phosphaturic effects of injected PTH [19]. The demonstration that PTH administration
in PHP patients failed to determine the expected physiological response and confirmed that the metabolic defect underlying PHP
can be accounted for a lack of responsiveness to PTH action, via its GPCR PTHR1, in target tissues [20].
In the renal proximal tubule, PTH resistance determines a defect in the generation of active 1,25 dihydroxyvitamin D3 by the
loss of the transcriptional induction of the 25-hydroxyvitamin D 1-α hydrolase gene. Because of the different site of action of
the anticalciuric (distal tubules) and the phosphaturic (proximal tubule) effects of PTH, PHP patients preserve normohypocalci-
uria and renal function but develop hyperphosphatemia, as the defective renal response occurs only in the proximal tubule. PTH/
1,25-dihydroxyvitamin D promote calcium ions absorption in the intestine, via the basolateral membrane channel calbindin/TR-
PV6 and membrane pumps and transporters on the latter membrane. Moreover, PTH enhances bone resorption by osteoclasts and
the release of calcium to the circulation, in a osteoblast-mediated manner [21–25].
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Fig. 2. Schematic illustration of GNAS, PRKAR1A and PDE4D genes. For each gene, the genomic structure (gDNA) and encoded functional domains (protein do-
mains) are shown. UTR, untranslated region; GTP, guanosine triphosphate; AC, adenylate cyclase; GPCR, G protein coupled receptor; DD, dimerization domain;
IS, inhibitory site; NBD, nucleotide-binding domain; UCR, upstream conserved region; CAT, catalitic.
The identification of defective Gs activity in erythrocyte membranes from PHP patients showed that the hormone resistance
derived from Gs inability to correctly activate the signal transduction cascade, consisting GPCRs and several downstream intra-
cellular effectors, including the Gs, the cAMP-dependent protein kinase A (PKA) and cAMP-specific phosphodiesterases (PDEs)
[2,5,6,26,27] (Fig. 1).
The discovery of the associated molecular defect, namely heterozygous loss of function (LoF) mutations in the GNAS gene
encoding for Gsα, confirmed the Gs pathogenetic role in the PHP phenotype [7,28,29].
Further studies allowed to deeply characterize GNAS locus, a complex imprinted locus mapping to chromosome
20q13.2–13.3, and demonstrated that Gsα expression is subject to tissue-specific imprinting, with a predominant maternal expres-
sion in specific human tissues (i.e. proximal renal tubules, pituitary gland, gonads, and thyroid) [30–38].
A paternal-specific imprinting pattern of GNAS differentially methylated regions (DMR) on both alleles was associated with
a clinical phenotype characterized by renal resistance to PTH and mild resistance to TSH in the absence of other endocrine or
physical abnormalities, thus including PHP also among imprinting disorders [35,39].
Despite the high detection rate of GNAS molecular defects, a subset of patients with a clinical suspect of PHP still lacked a
confirming molecular diagnosis, hence additional molecules involved in the cAMP signaling cascade were screened and genetic
alterations within PRKAR1A (cAMP-dependent protein kinase type I-α regulatory subunit) and PDE4D (cAMP-specific phospho-
diesterase 4D) were discovered and associated to ACRDYS [40–42] (Fig. 2).
Hormone resistances and clinical presentation
The identification of hormone resistance is based upon the observation of increased hormone levels associated with a reduc-
tion in the peripheral response to the hormone itself (Table 1).
Resistance to PTH
The diagnosis of PTH resistance is based on the observation of low or normal calcemia, elevated phosphatemia and elevated
serum PTH in the absence of vitamin D deficiency. It can be definitively ascertained using recombinant PTH [1–33], either as an
infusion test based on the Ellsworth–Howard test or as a subcutaneous challenge [43].
Usually PTH resistance is absent at birth, but gradually develops during infancy or childhood. Being conserved the antical-
ciuric action exerted at the level of the distal tubule, patients show normo-hypocalciuria and life-long normal renal function in
the absence of kidney stones. This latency of PTH resistance seemed to derive from the temporary physiological biallelic ex-
pression of maternal and paternal Gsα alleles renal proximal tubules during early postnatal development. Hyperphosphatemia, if
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Table 1
Table summarizing PHP diagnostic criteria.
Biochemical signs
Major laboratory findings:
• PTH resistance: raised serum PTH levels, hypocalcemia and hyperphosphatemia, in the absence of vitamin D deficiency.
Additional laboratory findings:
• TSH resistance: raised serum TSH levels, usually in the absence of anti-thyroid antibodies and in the presence of normal thyroid scan.
• Resistance to gonadotropins: elevated LH and FSH levels, low oestradiol/testosterone levels.
• GHRH resistance: blunted GH response to provocative tests.
Clinical signs
• Findings associated with acute or chronic hypocalcemia: nervous hyper-excitability with paresthesia, cramps, tetany, hyperreflexia, convulsions and tetanic
crisis – cataracts - basal ganglia calcifications.
• Secondary amenorrhea and/or infertility.
• Reduced growth velocity (in children), short stature.
• AHO features (at least brachydactyly and/or heterotopic ossifications are required):
- Brachydactyly (shortening of fourth and/or fifth metacarpals defined as the metacarpal sign and/or shortening below -2SDS at the metacarpophalangeal
profile pattern in at least one metacarpal bone or distal phalanx)
- Ectopic ossifications (either clinically evident or at X-ray)
- Obesity (BMI >30 kg/m ⁠2 in adults and >97th centile in children)
- Round face
- Intellectual disabilities, defined in case of history of delayed motor and/or speech milestones or need of extra help in pre-school or mainstream school.
untreated, enhances the defect in the generation of 1,25-dihydroxyvitamin D consequent to renal resistance to PTH, further con-
tributing to the decrease of serum calcium. The detection, during physical examination, of positive Chvostek sign (twitching of
facial muscles after tapping the facial nerve just in front of the ear) and/or Trousseau sign (carpal spasm after maintaining an arm
blood pressure cuff at 20 mm Hg above the patient's systolic blood pressure for 3min) may reveal hypocalcemia. Patients may
develop features such as basal ganglia calcifications and cataracts as effects of chronic hypocalmia, hyperphosphatemia and, more
importantly, elevated Ca × P product [9,10,44].
The management of PTH resistance has the objective to maintain calcemia and phosphatemia within normal ranges while
avoiding hypercalciuria and preventing bone resorption. The main treatments are active vitamin D analogs, calcitriol or alfacalci-
dol, and calcium supplements.
Resistance to other hormones
The identification of PTH resistance leads to the investigation for other hormone resistances, thus genetic disorders causing a
metabolic disorder. With interindividual variability in severity and time course, patients also display resistance to other GPCRs
acting hormones, such as TSH, gonadotropins, and GHRH [13,45–55].
TSH resistance is seldom detected during the neonatal screening for congenital hypothyroidism, but it develops more often
over childhood or adolescence. Clinically patients present mild resistance, characterized by elevated TSH levels, with normal/
slightly low free thyroxine levels, no goiter and no antithyroid antibodies [47–49]. The treatment is L-thyroxin administration to
reach a normal TSH level.
As for gonadotropins resistance, the relation with increased basal or GnRH-stimulated levels of circulating gonadotropins still
needs to be confirmed, although female patients usually manifest hypogonadism, or rather delayed or incomplete sexual matura-
tion, amenorrhea/oligomenorrhea and/or infertility [50].
Deficiency in GH secretion secondary to GHRH resistance was reported in a large subset of PHP patients. Additional hormone
defects described in small series of PHP patients include prolactin deficiency, blunted plasma cAMP responses to glucagon and
isoproterenol, resistance to calcitonin and reduced insulin sensitivity [50–55].
The current knowledge on ACRDYS confirmed that PRKAR1A defects were frequently associated with multihormone resis-
tance, whereas, in case of PDE4D mutations, hormonal defects were present only in a subset of patients. Most patients displayed
resistance to PTH and TSH, and a small percentage showed an altered response to FSH associated with cryptorchidism and/or
lack of puberal spurt [56].
Additional clinical features
Albright hereditary osteodystrophy is a clinical entity encompassing a series of heterogeneous and nonspecific clinical find-
ings including rounded face, short stature, early-onset central obesity, and variable degrees of mental retardation. Such clinical
features are frequently described also in patients affected with acrodysostosis, making the differential diagnosis even more com-
plicated [9,12,14,56].
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The evaluation of auxological parameters allows to find short stature, defined as height below the 3rd percentile for chrono-
logical age, and obesity, defined as Body Mass Index (BMI) above the 97th percentile in children (SDS ≥ 1.88) and above 30 kg/
m ⁠2 in adults [12,56].
One of the most specific features of AHO are heterotopic intramembranous ossifications. Such calcified nodules are often lim-
ited to the dermis and subcutaneous tissues and can be found on physical examination as palpable hard nodules, whose number
and extension are highly heterogeneous.
Brachydactyly, defined as the shortening of III, IV and V metacarpals, and I distal phalanx, derives from the premature closure
of the growth plate and associated with coning of the epiphysis. Its presentation is highly variable and is often asymmetric, and,
to avoid a misdiagnosis, the construction of the metacarpophalangeal pattern profile after posterioanterior left hand radiographs
is used. It can be absent at birth, but it become apparent during infancy/childhood. Brachydactyly showed to be the most frequent
feature of ACRDYS, as present in more than 90% of patients [56,57].
AHO seems to be associated also with musculoskeletal abnormalities including spinal cord compression and carpal tunnel
syndrome [58,59]. In ACRDYS, cone-shaped epiphyses and facial dysmorphism are often observed [56].
Frequency and severity of neurocognitive abnormalities in PHP patients, such as mental retardation, developmental delay and
emotional disorders, are not well established, with an apparent discrepancy between the adult (27%) and the pediatric populations
(64%) [12,60]. Mental/behavioural defects seemed to have different frequencies between ACRDYS subtypes, affecting about half
of PRKAR1A mutated patients and up to 95% of the PDE4D mutated patients [56].
Recent data suggested that patients with PHP may present intrauterine growth defects. A growth retardation leading to low
birth weight and length was described in those with a paternally-inherited GNAS disease, while an opposite phenotype with
increased intrauterine growth was documented in PHP1B subjects affected with the autosomal dominant form of the disorder
[61,62]. Intrauterine growth retardation was described in about 15% of ACRDYS subjects bearing a PRKAR1A genetic variant
[56].
Further additional recurring comorbidities, deserving investigation in larger cohorts in order to define their relationship with
ACRDYS, are hearing loss, recurrent otitis media, intracranial hypertension, shypodeformity of knees and shoulders, and atophy/
rhinitis/eczema [56].
Molecular diagnosis and genetic counseling
The non-responsives of target organs to hormones, despite sufficient/elevated hormone levels, mimics the deficiency of the
hormone itself. Such resistances mostly derive from inactivating mutations affecting hormone receptors, while multiple hormone
resistances associated with alterations of the GPCRs signaling are an unusual form of hormone resistance as molecular defects af-
fect Gsα, Prkar1a and Pde4d proteins, or rather downstream effectors of the GPCR PTHR1. As previously stated, the clinical and
molecular overlap among disorders affecting the cAMP pathway makes performing the correct molecular diagnosis challenging
and time consuming, thus, in Fig. 3, we resume the flowchart to analyze patients after the clinical assessment.
GNAS genetic defects
The first GNAS inactivating mutation was described in 1990 and since then more than 200 genetic variants distributed through
the GNAS gene have been discovered, both point mutations (missense, nonsense, frameshift, and splice site) and small/large dele-
tions or insertions. The only mutational hot spot described up to now is a 4-bp deletion in exon 7, c.568_571del. All GNAS exons
are affected with different frequency, although exons 1 and 7 host about 20% each. Most of these genetic defects are private mu-
tations, and the few recurring de novo mutations suggest the derivation from a common molecular mechanism rather than from a
founder effect [7,63–67].
GNAS genetic defects are subject to autosomal dominant inheritance, thus offsprings of a PHP patient have a 50% recurrence
risk and the detection of pathogenetic variants provides the possibility of predictive genetic testing in relatives as well as prenatal
diagnosis [63–69].
To note that the phenotypic overlap among different disorders affecting the cAMP pathway represents a challenge to perform
differential diagnosis and, in case of negative GNAS mutation screening, patients should be screened also for the presence of
GNAS imprinting and of genetic variants in PRKAR1A and PDE4D genes [12,15,16].
GNAS epigenetic defects
Reports about multi-generation families with PHP showing a marked excess of maternal transmission, suggested the involve-
ment of genomic imprinting. The characterization of the GNAS locus and its transcripts demonstrated that Gsα expression is
subject to tissue-specific imprinting and that PHP1B patients displayed a paternal-specific patterns of cytosine methylation at
GNAS DMRs of their maternally inherited alleles. Most cases were sporadic, being the only affected individuals in a given family
with no underlying known genetic lesion, thus the recurrence risk could not be determined. In a small subset of sporadic PHP1B
(spor-PHP1B) patients, the LOI affecting GNAS DMRs was associated with uniparental disomy (UPD) of chromosome 20, which
occurrence, in the absence of a parental translocation, was expected to be less than 1% [70–73].
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Fig. 3. Flowchart summarizing a molecular diagnostic algorithm for patients with multiple hormone resistance suspected of having a disorder linked to defective
Gsα–cAMP signaling. According with the starting clinical suspicion, we propose how to perform a multistep analysis of patients to reach the molecular diagnosis.
The familial form of the disease is maternally transmitted in an autosomal dominant manner, with a 50% recurrence risk. Au-
tosomal dominant PHP type 1B (AD-PHP1B) is typically characterized by an isolated loss of methylation at the exon A/B DMR
due to microdeletions disrupting the ICR located into the STX16 gene or, less frequently, by a LOI at all maternal GNAS DMRs
due to deletions removing the NESP55 DMR [74–79].
PRKAR1A and PDE4D genetic defects
PRKAR1A and PDE4D heterozygous genetic variants, affecting different functional domains, were associated to ACRDYS.
Such mutations are mainly private, and the only recognized mutational hot spot is the PRKAR1A c.1102C > T nonsense mutation,
p.(Arg368X). As for the PDE4D gene, mutations are confined to single kindreds, with the exception of 4 recurring variants af-
fecting the catalytic unit (c.803T > C, c.1586A > C, c.1835G > A and c.1850T > C) [40–42,56,80–85].
Genetic defects causing ACRDYS are autosomal dominant. The predictive genetic testing in relatives of mutated patients can
be performed as offsprings have a 50% recurrence risk.
Classification: from the classical towards a novel nomenclature and classification
Since the first description of PHP, several clinical variants of this disorder have been reported and today the term Pseudohy-
poparathyroidism encompasses a group of rare, related and deeply impairing diseases, and performing a proper differential diag-
nosis among the various forms may be sometimes challenging.
The classical, still in use, classification is based on the presence/absence of specific clinical and biochemical signs, does not
include molecular defects as a criterion to stratify patients and does not include all conditions deriving from Gsα/cAMP/PKA
pathway molecular defects. The increasing knowledge of these disorders made this classification outdated and demonstrated the
need for a novel and more effective one. Recently, a proposal for a new terminology has been proposed by the European net-
work on PHP, together with a novel classification that should provide patients with an unambiguous diagnosis based on clinical/
biochemical/molecular criteria [12,15,16]. “Inactivating PTH/PTHrpP signaling disorder” (iPPSD) is the proposed new nomen-
clature for this heterogeneous group of rare diseases and the different iPPSD subclusters encompassing disorders associated with
multiple hormone resistance are reported below and resumed in Table 2.
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Table 2
Classification of pseudohypoparathyroidism and related syndromes. Subtypes associated with multiple hormone resistance are highlighted in bold. OMIM, online
Mendelian inheritance in man; AHO, Albright hereditary osteodystrophy; DMRs, differentially methylated regions; LoF, loss of function; LoI, loss of imprinting;
patUPD, paternal uniparental disomy; BOCD, Blomstrand chondrodysplasia; HTNB, hypertension and brachydactyly syndrome.
Classical classification Novel classification OMIM Phenotype
Main molecular
determinants
BOCD EIKEN
SYNDROME
iPPSD1 #215045
#600002
skeletal dysplasia, retarded
ossification
PTHR1 mutations
PHP1A iPPSD2 # 103580 multiple hormone
resistance, AHO
Maternal LoF GNAS
mutations, GNAS deletions,
LoI at GNAS DMRs
PPHP/AHO iPPSD2 # 612463 AHO Paternal LoF GNAS
mutations, GNAS deletions
POH iPPSD2 # 166350 heterotopic ossifications Paternal LoF GNAS
mutations
PHP1B iPPSD3 # 603233 multiple hormonal
resistance, rare signs of
AHO
LoI at the GNAS DMRs
(sporadic), isolated LoM at
the A/B DMR (AD –
maternal STX16 deletion),
patUPD20, maternal NESP
and/or AS deletion
ACRDYS1 iPPSD4 # 101800 skeletal dysplasia, AHO-
like features and multiple
endocrine abnormalities
PRKAR1A mutations
ACRDYS2 iPPSD5 # 614613 skeletal dysplasia, AHO-
like features and
intellectual disabilities
PDE4D mutations
HTNB iPPSD6 #112410 brachydactyly,
hypertension
PDE3A mutations
/ iPPSDx / / No (epi)genetic defect in
known genes identified
during investigation
/ iPPSDn+1 / / Novel gene/molecular
defect to be discovered
PHP1A/PHP1C and POH, or iPPSD2
The iPPSD2 cluster includes all clinical presentations of loss-of-function Gsα mutations: Pseudohypoparathyroidism type 1A
(PHP1A, MIM103580), Pseudohypoparathyroidism type 1C (PHP1C, MIM612462), Pseudopseudohypoparathyroidism (PPHP,
MIM612463) and Progressive Osseous Heteroplasia (POH, MIM166350).
Patients with PHP1A, affected by maternally-derived point mutations in GNAS exons 113 or structural rearrangements in-
volving part or the whole GNAS locus, clinically present both AHO features and resistance to several GPCRs-acting hormones
(PTH, TSH, gonadotropins and GHRH) [7,66–69].
The same mutations, when affecting the paternal allele, lead to PPHP, in which AHO occurs in the absence of endocrine ab-
normalities. PHP1A and PPHP may coexist within the same family but never in the same sibship [63,64].
PHP1C is clinically indistinguishable from PHP1A, being characterized by multihormone resistance and the presence of signs
of AHO. Actually the only way to differentiate these two PHP variants is the measurement of Gsα activity in erythrocytes', fi-
broblasts' or platelets' membranes, usually normal in PHP1C patients and 50% reduced in PHP1A subjects [86].
POH is a recently described rare disorder of mesenchymal differentiation, associated with paternally-inherited GNAS inacti-
vating mutations, characterized by ectopic bone formation in dermis, skeletal muscle and deep connective tissues. Recent reports
documented the existence of patients showing also typical AHO features, such as short stature and brachydactyly [87–89].
PHP type 1B, or iPPSD3
The iPPSD3 subgroup includes all disorders associated with changes in the methylation pattern of GNAS DMRs, includ-
ing both primary epigenetic defects, or rather broad or partial GNAS loss of Imprinting (LOI), and conditions secondary to
UPD(20)pat and deletions within STX16 and/or NESP [70–79].
At its first description Pseudohypoparathyroidism type 1B (PHP1B, MIM603233) was presented as a clinical condition char-
acterized by renal resistance to PTH in the absence of other endocrine or physical abnormalities. Subsequently, TSH resistance
was also documented in large subsets of patients, thus identifying also this subtype as characterized by multi-hormone resistance.
The recent description of GH deficiency in affected monozygotic twins suggested that also the GHRH-R signaling could be com-
promised [90–95].
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ACRDYS type 1 and type2, or iPPSD4 and iPPSD5 respectively
iPPSD4 and iPPSD5 represent the two subtypes of Acrodysostosis type 1 (ACRDYS1, MIM101800) and type 2 (ACRDYS2,
614613) associated with PRKAR1A and PDE4D defects, respectively.
ACRDYS refers to a heterogeneous group of rare genetic congenital malformation syndromes, whose hallmarks are skeletal
dysplasia with AHO-like features, such as brachydactyly type E, progressive growth failure, mental retardation and facial dysos-
tosis (broad face with widely spaced eyes, maxillonasal hypoplasia and flattening of the nasal bridge).
The first case presenting also biochemical abnormalities dates back to 1977, but nowadays the presence of resistance to mul-
tiple hormones that bind GPCRs has been well documented, especially in patients carrying PRKAR1A mutations (ACRDYS1 or
iPPSD4). To note that up to 20% of ACRDYS2 patients show an altered response to follicle-stimulating hormone, cryptorchidism
and/or lack of puberal spurt [56].
Conclusions
Patients with PHP and related disorders face heterogeneous problems from early childhood to adulthood, including severe
alterations of mineral metabolism potentially leading to seizures, other endocrine deficiencies leading to hypothyroidism, hypog-
onadism and GH deficit, important growth impairment independently of the hormonal status, ectopic ossifications with potential
severe mobility limitation, skeletal issues, cognitive and psychomotor impairment. Given this highly heterogeneous clinical pic-
ture, clinicians often lack expertise to manage all these aspects.
In addition, this group of disorders is caused by different and complex genetic and epigenetic defects, so that often getting a
correct molecular diagnosis may be also difficult and time-consuming for both patients, families and physicians.
Finally, there is a lot of confusion and overlap as to the nomenclature and classification of these heterogeneous but still closely
related diseases.
Summary
Metabolic disorders deriving from the non-responsiveness of target organs to hormones, which manifest clinically similar to
the deficiency of a given hormone itself, derive from molecular alterations affecting specific hormone receptors.
Pseudohypoparathyroidism (PHP) includes different metabolic disorders characterized by physical findings that variably com-
prise short bones, short stature, a stocky build, ectopic ossifications, and endocrine defects that commonly include resistance to
multiple hormones. PHP and its related disorders vary with regards to clinical and endocrine presentation and severity between
affected individuals with considerable clinical and molecular overlap.
As for its pathogenesis, PHP exemplifies an unusual form of hormone resistance as the underlying molecular defect is a partial
deficiency of Gsα, a key regulator of cAMP signaling pathway, rather than the hormone receptor itself. Despite the first descrip-
tion of this disorder dates back to 1942, recent findings unveiled complex epigenetic alterations beside classical mutations at the
GNAS complex gene as the molecular basis for PHP main subtypes. Moreover, mutations in the PRKAR1A and PDE4D genes,
both crucial as GNAS for cAMP-mediated signalling, have been demonstrated in patients with acrodysostosis, a disease of bone
formation and endocrine disturbances with many shared clinical characteristics.
In particular, resistance to hormones such as PTH, TSH, gonadotropins and GHRH may be variably present in this group of
diseases, so that the clinical and molecular overlap among these different but related disorders represents a challenge for endocri-
nologists as to differential diagnosis and genetic counseling.
Practice points
• The term PHP encompasses a heterogeneous group of rare and impairing metabolic diseases, all characterized by end-or-
gan resistance to the action of different hormones, primarily PTH. Endocrine alterations often include, with interindi-
vidual variability in severity and time course, also resistance to other hormones that act through GPCRs, such as TSH,
gonadotropins, and GHRH.
• The lack of responsiveness to PTH, which results in hypocalcemia, hyperphosphatemia and inappropriately high serum
PTH levels, usually develops over the first years of life, with high serum phosphate and elevated PTH generally preceding
calcium reduction. The management of PTH resistance has the objective to maintain calcemia and phosphatemia within
normal ranges, lowering PTH as much as possible while avoiding hypercalciuria.
• Most patients become clinically resistant to TSH over childhood or adolescence, but hypothyroidism may be sometimes
detected at neonatal screening. Generally, TSH resistance is mild, with normal or slightly low thyroid hormone levels, no
goiter and absence of antithyroid antibodies. Treatment with L-thyroxin is aimed to normalize TSH levels, as in any other
form of primary hypothyroidism.
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• Clinical evidence of hypogonadism, particularly in females, is usually manifested as delayed or incomplete sexual matu-
ration, amenorrhea or oligomenorrhoea, and/or infertility.
• Patients frequently display additional heterogeneous features, referred to as Albright's hereditary osteodystrophy (AHO),
such as brachydactyly, ectopic ossifications, short stature and mental retardation.
• The term acrodysostosis (ACRDYS) represents a group of rare skeletal disorders that may associate with the resistance
to multiple hormones including PTH and TSH. Patients frequently display additional heterogeneous features, such as
progressive growth failure with short stature, advanced bone age, obesity, severe brachydactyly, nasal and/or midfacial
hypoplasia and variable intellectual/developmental/behavioural disabilities.
• Recently, the term “inactivating PTH/PTHrpP signaling disorder” (iPPSD) has been proposed to include all these het-
erogenous but similar rare disorders, together with a novel classification that should provide an unambiguous diagnosis
based on both clinical and molecular criteria.
Research agenda
Given the lack of strong evidence-based data, particularly for management of these patients, international collaboration and
long-term clinical trials looking at both the natural history and the outcome of treatments are urgently needed. In particular,
the research agenda should focus on:
• Extensive and systematic data on growth pattern related to endocrine function, bone maturation, pubertal development
and gonadal function, fertility, mineralization status.
• Identification of factors that contribute to the development and progression of ectopic bone formation.
• Identification of new genes involved in the PTH/PTHrP signaling cascade and their association with as-yet-unresolved
cases with PHP and related disorders.
• Optimization of calcium, phosphate and PTH levels during active treatment for PTH resistance, especially related to
poorly characterized long-term complications.
• Indications, doses, efficacy, optimal timing and indications for rhGH use in GH-deficient patients.
• Long-term quality of life.
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